Phibro Animal Health Reports Q3 FY2024 Results; Updates Guidance, Plans Zoetis Acquisition

PHIBRO ANIMAL HEALTH CORP

2024-Q3 EPS reported $0.04 revenue$744,515,000

Net sales for Q3 ended March 31, 2024 were $263.2M, up 7% YoY; Animal Health segment grew 10%.
Adjusted EBITDA increased 9% to $29.7M; adjusted diluted EPS rose to $0.31 from $0.29.
Affirmed FY2024 net sales guidance of $980M-$1.02B and Adjusted EBITDA of $106M-$112M.
Signed agreement to acquire Zoetis' Medicated Feed Additive portfolio to enhance product offerings.
Vaccine sales surged 26% and MFA and other sales increased 16% in the quarter.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PHIBRO ANIMAL HEALTH CORP reported the fiscal quarter ended March 31, 2024 results: revenue $263.2 million, net income $8.4 million, EPS $0.21.

Period: the fiscal quarter ended March 31, 2024
Revenue: $263.2 million
Net income: $8.4 million
EPS: $0.21
Result: reported results

Exact text from the filing

Net sales of $263.2 million, an increase of $17.6 million, or 7% - Net income of $8.4 million, a decrease of $1.6 million - Diluted earnings per share of $0.21, a decrease of $0.04

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PHIBRO ANIMAL HEALTH CORP reported the fiscal year ending June 30, 2024 results: revenue $980 million to $1.020 billion, net income $7 million to $12 million, EPS $0.17 to $0.30.

Period: the fiscal year ending June 30, 2024
Revenue: $980 million to $1.020 billion
Net income: $7 million to $12 million
EPS: $0.17 to $0.30
Result: guidance update

Exact text from the filing

We affirm our previously issued fiscal year 2024 guidance for the following measures: – Net sales of $980 million to $1.020 billion – Adjusted EBITDA of $106 million to $112 million – Adjusted net income of $42 million to $47 million – Adjusted diluted EPS of $1.04 to $1.16 – Adjusted effective tax rate of 28% to 30% We have updated our fiscal year 2024 guidance for the following measures: - Net income of $7 million to $12 million - Diluted EPS of $0.17 to $0.30

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

PHIBRO ANIMAL HEALTH CORP filing history →

Source: SEC EDGAR

accession 0001558370-24-007371

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.